Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

NCT06442566
View directory record Official record
Conditions
Opioid Withdrawal, Chronic Pain
Interventions
Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Not yet recruiting Phase 4 Interventional

Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty

NCT07097493
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Liposomal Bupivacaine, Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 4 Interventional Results available

Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization

NCT05118204
View directory record Official record
Conditions
Substance Use Disorders, Opioid-use Disorder, Chronic Pain
Interventions
BUP microdose induction, TAU, Linkage to outpatient BUP treatment
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Not listed Phase 1Phase 2 Interventional

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026
View directory record Official record
Conditions
Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions
BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
Drug
Lead sponsor
Gauda, Estelle B., M.D.
Individual
Eligibility
Up to 7 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

NCT03188185
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, ALKS 5461 Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting Phase 2 Interventional

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

NCT06521476
View directory record Official record
Conditions
Central Sleep Apnea Comorbid With Opioid Use
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
Sanjay R Patel
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

NCT01642030
View directory record Official record
Conditions
Opioid Dependence, Pain, Addiction
Interventions
Placebo, Hydromorphone, Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 19, 2026, 4:52 PM EDT
Not listed No phase listed Observational

Improving Treatment and Recovery Services for Individuals With Opioid Problems

NCT05129813
View directory record Official record
Conditions
Counseling
Interventions
Recovery Guide Counseling
Behavioral
Lead sponsor
Howard University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

NCT00000318
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational Results available

Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior

NCT03221309
View directory record Official record
Conditions
HCV, Buprenorphine, PreP
Interventions
Evaluate model of care for HCV-infected adults with on-going opioid misuse
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Active, not recruiting Not applicable Interventional

Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder

NCT04257214
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psychosocial treatment
Behavioral
Lead sponsor
Philadelphia College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Atlantic City, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pioglitazone to Treat Opioid Withdrawal Symptoms

NCT01517165
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting No phase listed Observational

fMRI and Opioid Abstinence

NCT06651333
View directory record Official record
Conditions
Drug Use Disorder, Opioid Dependence, Opioid-Related Disorders, Opioid Use, Opioid Abuse
Interventions
fMRI
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational

Fetal Neurobehavioral Development in Methadone Maintained Pregnancies

NCT00067184
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Toitu 320/325
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia

NCT00539123
View directory record Official record
Conditions
Opiate Dependence
Interventions
behavioral drug and HIV risk reduction counseling (BDRC), abstinence-contingent buprenorphine (ACB)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients

NCT04650386
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Psychosocial support determined by adaptive treatment algorithm
Behavioral
Lead sponsor
Public Health Management Corporation
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase X - 15

NCT00000233
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
34 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

NCT04752384
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Buprenorphine, Tramadol, Oral Mucositis (OM) Pain App
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine

NCT07278518
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Patient Decision Aid for Opioid Use Disorder
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

NCT06087991
View directory record Official record
Conditions
Opioid Abuse
Interventions
Implementation of the BINDeR-Tx service model
Behavioral
Lead sponsor
Jerry Cochran
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

NCT02672111
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 19, 2026, 4:52 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Peer Recovery Support for Opioid Use Disorder Treatment Retention

NCT07620171
View directory record Official record
Conditions
Opioid Use Disorder, Peer Recovery Supporters, Peer Recovery Coaching, Primary Care, Buprenorphine
Interventions
Peer Support
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 4:52 PM EDT